InDex Pharmaceuticals printlogo
  • About us
  • Pipeline
  • Cobitolimod
  • CONDUCT
  • DiBiCol
  • Investors
  • Media
  • Contact
SWE
Investors
    • About Us
      • InDex Pharmaceuticals in brief
      • Business model
      • Corporate governance
        • General meetings
        • Nomination committee
        • Board of directors
          • Work of the board of directors
        • Management
        • Remuneration and incentive programmes
        • Auditors
        • Articles of association
      • Scientific Advisory Board
      • Expert panel of key opinion leaders
    • Pipeline
      • Technology platform & pipeline
    • Cobitolimod
      • The Clinical Study CONDUCT
      • Cobitolimod treatment
      • Interview with Emma – about living with ulcerative colitis
      • Scientific articles
    • CONDUCT
      • The Clinical Study CONDUCT
      • Study design
      • Presentations and interviews on CONDUCT
    • DiBiCol
      • DiBiCol Diagnostic
      • To order DiBiCol Sampling kit
    • Investors
      • Company presentation
      • InDex Pharmaceuticals on Nasdaq First North Growth Market
      • The share
        • Dividend and dividend policy
        • Shareholders
      • Interim Reports
      • Annual Reports
      • Prospectus
      • Press releases
      • Presentations
      • Capital Markets Day in Stockholm – April 25, 2018
      • Financial calendar
      • Subscribe
      • Nasdaq First North Growth Market Certified Adviser
      • IR contact
      • Analysts
    • Media
      • Press releases
      • Image bank
      • Subscribe
      • Media contact
    • Contact
      • Mailing address
      • Visiting address
      • IR contact
      • Nasdaq First North Growth Market Certified Adviser
      • Media contact
      • To order DiBiCol Sampling kit
  • Investors
    • Company presentation
    • InDex Pharmaceuticals on Nasdaq First North Growth Market
    • The share
      • Dividend and dividend policy
      • Shareholders
    • Interim Reports
    • Annual Reports
    • Prospectus
    • Press releases
    • Presentations
    • Capital Markets Day in Stockholm – April 25, 2018
    • Financial calendar
    • Subscribe
    • Nasdaq First North Growth Market Certified Adviser
    • IR contact
    • Analysts

Financial calendar

Upcoming events
  • 2016
  • 2017
  • 2018
  • 2019
  • 2020

Annual General Meeting

20 April 2020

Read more

Interim report Q1

7 May 2020

Read more

Interim report Q2

26 August 2020

Read more

Interim report Q3

25 November 2020

Read more

Ulcerative colitis

Ulcerative colitis is a chronic inflammatory bowel disease of unknown cause.

Symptoms include frequent stools, diarrhea, blood in stool, abdominal pain, fever, weight loss and anemia. Standard treatment includes anti-inflammatory, immunosuppressive and biological drugs.

A substantial percentage of patients with moderate to severe active ulcerative colitis will not respond to available therapies or will eventually develop tolerance to treatment.

Learn more

Cobitolimod

Cobitolimod (Kappaproct, DIMS0150) is a potential new medication for patients with moderate to severe active ulcerative colitis.

Cobitolimod is a first in class treatment that provides a local anti-inflammatory effect which in clinical trials has shown to result in significant improvements of the major clinical symptoms.

Cobitolimod has very limited systemic absorption. This gives the drug a favorable safety profile, in sharp contrast to many approved treatments.

Learn more
InDex Pharmaceuticals Holding AB|Registration number: SE 559067-6820
Phone: +46 8 508 847 30 | Fax: +46 8 508 847 39 | Cookies | Trademarks | Contact us